Cognition Therapeutics (CGTX)
Developing zervimesine for Lewy body dementia psychosis.
Something off on this page? Send us feedback.
Develops zervimesine, an oral small molecule being studied for psychosis associated with dementia with Lewy bodies and early Alzheimer's disease. A clinical-stage developer, it has no approved products or sales and concentrates all current programs in one molecule.
Develops zervimesine, an oral small molecule designed to modulate the sigma-2 receptor complex and prevent toxic protein oligomers from disrupting neuronal synapses. Its lead development focus is psychosis associated with dementia with Lewy bodies, while an NIH-funded study continues in early Alzheimer's disease. A prior geographic-atrophy study is no longer identified as a current priority.
Operates as a clinical-stage research-and-development business with no approved product or product sales. Development is organized around FDA approval, with executive operations in Purchase, New York and a historic scientific base in Pittsburgh.
All clinical programs rely on zervimesine, and the company depends on FDA alignment, NIH reimbursements, additional capital, and third-party manufacturers, research organizations, and trial sites to advance it.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Jun 22, 2026 | H.C. Wainwright | Reiterate | Rating: —Target: — | Target: $3 |
| Dec 19, 2024 | B. Riley Securities | Upgrade |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $34.0M · Total debt $511.0K · Total assets $38.9M · Shareholders' equity $33.0M
- Revenue
- $0
- Operating income
- −$7.7M
- Net income
- −$3.9M
No dividends on record.
| Institutions | 23.84% | 22.67M shares | |
|---|---|---|---|
| 67 holders · as of Jun 30, 2026 | |||
| Insiders | 6.93% | 6.59M shares | |
| 9 holders · as of Jun 22, 2026 | |||
| Other | 69.23% | 65.83M shares | |
| remainder | |||
95.09M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Bios Capital Management, LPInstitution | 6.31% | 6.00M | as of Jun 30, 2026 |
Davenport & Co LLCInstitution | 4.48% | 4.26M | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 3.62% | 3.44M | as of Jun 30, 2026 |
Aaron G.L. FletcherInsiderdirector, 10 percent owner | 3.11% | 2.96M | filed Jun 22, 2026 |
Lisa RicciardiInsiderdirector, officer: CEO & President | 1.85% | 1.75M | filed Apr 20, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Apr 16, 2026 | Anthony Caggiano | officer: Chief Medical Officer | +10,000 | $1.11 |
| Apr 16, 2026 | Lisa Ricciardi | director, officer: CEO & President | +9,175 | $1.10 |
| Apr 16, 2026 | John Brendan Doyle | officer: Chief Financial Officer | +10,000 | $1.13 |
- Acadia Pharmaceuticals
Closest DLB-psychosis rival through an LBD pipeline and psychosis franchise.
- Eli Lilly
Approved anti-amyloid therapy in early Alzheimer's disease.
- Biogen
Leqembi co-commercialization spans early Alzheimer's disease.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Cognition Therapeutics | $0.9880 | −1.20% | $89.5M | — | — | — | — |
| Acadia Pharmaceuticals | $26.71 | +1.19% | $4.52B | 11.9 | 29.9 | 4.0 | +16.4% |
| Eli Lilly | $1,169.46 | +0.39% | $1.10T | 39.1 | 28.6 | 13.8 | +47.7% |
| Biogen | $224.44 | +2.45% | $32.37B | 38.8 | 16.9 | 3.3 | +3.4% |
| Median | 38.8 | 28.6 | 4.0 | +16.4% |